Phenotypic susceptibility to antiretrovirals among clades C, F, and B/F recombinant antiretroviral-naive HIV type 1 strains

AIDS Research and Human Retroviruses

Volumn 29, Issue 6, 2013, Pages 880-886

  Sucupira, Maria Cecilia A ^a   Munerato, Patricia ^a,b   Silveira, Jussara ^c   Santos, André F ^d   Janini, Luiz Mário ^a   Soares, Marcelo A ^d,e   Diaz, Ricardo Sobhie ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Life Technologies Com E Ind de produtos do Brasil   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; BRAZIL; CLINICAL ARTICLE; CLINICAL EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE;

EID: 84877861441     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0259     Document Type: Article

References (30)

1. Youree BE and D'Aquila RT: Antiretroviral resistance testing for clinical management. AIDS Rev 2002;4:3-12
2. Dunne AL, Mitchell FM, Coberly SK, et al.: Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001;15:1471-1475
3. Munerato P, Sucupira MC, Oliveros MP, et al.: HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of Sao Paulo, Brazil. AIDS Res Hum Retroviruses 2010;26:265-273
4. Deforche K, Silander T, Camacho R, et al.: Analysis of HIV-1 pol sequences using Bayesian networks: Implications for drug resistance. Bioinformatics 2006;22:2975-2979
5. Accetturi CA, Pardini R, Novaes Pinto GH, Turcato G Jr, Lewi DS, and Diaz RS: Effects of CCR5 genetic polymorphism and HIV-1 subtype in antiretroviral response in Brazilian HIV-1-infected patients. J Acquir Immune Defic Syndr 2000;24:399-400
6. Abecasis AB, Deforche K, Snoeck J, et al.: Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005;19:1799-1806
7. Calazans A, Brindeiro R, Brindeiro P, et al.: Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005;191:1961-1970
8. Gonzalez LM, Brindeiro RM, Tarin M, et al.: In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003;47:2817-2822
9. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, and Soares MA: Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr 2003;34:520-526
10. Sucupira MC, Caseiro MM, Alves K, et al.: High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS 2007;21:116-128
11. Lole KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160
12. Salminen MO, Carr JK, Burke DS, and McCutchan FE: Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses 1995;11:1423-1425
13. Hertogs K, de Bethune MP, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276
14. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: 920-928
15. Verlinden Y, Vermeiren H, and Lecocq P: Assessment of the Antivirogram- performance over time including a revised definition of biological test cut-off values. In: XIVth International HIV DRUG RESISTANCE Workshop, Que'bec City, Que'bec, Canada, 2005
16. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70: 8270-8276
17. Servais J, Lambert C, Fontaine E, et al.: Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother 2001;45:893-900
18. Tanuri A, Vicente AC, Otsuki K, et al.: Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob Agents Chemother 1999;43: 253-258
19. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163
20. Soares EA, Santos AF, Sousa TM, et al.: Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2007;2:e730
21. Santos AF, Lengruber RB, Soares EA, et al.: Conservation patterns of HIV-1 RT connection and RNase H domains: Identification of new mutations in NRTI-Treated patients. PLoS ONE 2008;3:e1781
22. Yap SH, Sheen CW, Fahey J, et al.: N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007;4:e335
23. Kempf DJ, Isaacson JD, King MS, et al.: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75: 7462-7469
24. Hermans P, Schimt JC, Kabeya K, et al.: Virological response to salvage therapy at 6 months in patients with B and non-B subtypes. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002
25. Ananworanich J, Hirschel B, Sirivichayakul S, et al.: Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther 2006;11: 631-635
26. Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised noninferiority trial. Lancet 2006;368:476-482
27. Kempf DJ, King MS, Bernstein B, et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60
28. Swindells S, DiRienzo AG, Wilkin T, et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006;296:806-814
29. Delaugerre C, Flandre P, Chaix ML, et al.: Protease inhibitor resistance analysis in the MONARK trial comparing firstline lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009;53:2934-2939
30. Geretti AM, Harrison L, Green H, and Dunn D: Exploring the effect of HIV-1 subtype on virological and immunological responses to first-line HAART. In: 6th European HIV Drug Resistance Workshop, Budapest, 2008